StockData
Aprea Therapeutics, Inc. logo

Aprea Therapeutics, Inc. (APRE) stock

APRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$0.45+0.05 (+11.52%)

Close on Nov 17, 2026Market cap $5.71MP/E –Yield –

Aprea Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Aprea Therapeutics's enterprise value was -$35.73M on Nov 11, 2026, against -$6.18M a year earlier. Over the last 5 years it ranged from -$39.04M to $9.96M, with a median of -$11.75M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026-$35.73M–
2025Dec 31, 2025-$8.62M–
2024Dec 31, 2024-$8.37M–
2023Dec 29, 2023-$7.79M–
2022Dec 30, 2022-$15.82M–
2021Dec 31, 2021-$124.80K-104.0%
2020Dec 31, 2020$3.09M+63.1%
2019Dec 31, 2019$1.90M–

More Aprea Therapeutics figures

See a number that looks wrong?